Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.72 USD
Change Today +0.05 / 1.36%
Volume 23.2K
As of 8:10 PM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

bacterin international holdi (BONE) Key Developments

NYSE MKT Files Form 25 To Remove Bacterin International Holdings Common Stock From Listing

On May 6, 2015, the NYSE MKT filed a Form 25 with the Securities and Exchange Commission to remove Bacterin International Holdings, Inc.’s common stock from listing on the NYSE MKT. This will not have any effect on trading of common stock since the company previously transitioned trading of common stock on April 9, 2015 to the OTCQX marketplace under the ticker symbol "Bone".

Bacterin International Holdings, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Revenue Guidance for 2015

Bacterin International Holdings, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. First quarter 2015 revenue was approximately $9.5 million, an increase of 6.6% compared to approximately $8.9 million for the same period during 2014. Sequentially, first quarter 2015 revenue increased 4.6% over fourth quarter 2014 revenue of $9.1 million. The reported first quarter 2015 revenue represents a new record and the sixth consecutive quarter of increased year-over-year revenue growth since Dan Goldberger joined Bacterin as Chief Executive Officer in August 2013. The first quarter 2015 loss from operations was approximately $1.7 million, compared to approximately $1.2 million in the first quarter of 2014. The increased loss primarily reflect the Company's ongoing execution of its strategy to increase and enhance field sales assets to drive future revenue growth as well as the Company's expanded product development initiatives. The reported first quarter 2015 net loss of $4.2 million is essentially flat when compared to $4.1 million for the same period during 2014. EBITDA for the first quarter of 2015 was a loss of $1.3 million compared to a loss of $0.7 million for the same period during 2014 and $1.1 million for the fourth quarter of 2014. The company incurred approximately $302,000 of expenses in the first quarter that will be eliminated over the second half of 2015. Excluding this figure, the EBITDA loss for the first quarter of 2015 would have been approximately $966,000. Loss from operations before impairment was $1.7 million against $1.2 million a year ago. Net loss from operations before benefit for income taxes was $4.2 million against $4.1 million a year ago. Net cash used in operating activities was $2.1 million against $2.2 million a year ago. Purchases of property and equipment and intangible assets were $48,768 against $54,933 a year ago. For the full year 2015, the company reaffirmed its revenue guidance of approximately $40 million to $42 million, which compares to $35.3 million reported for 2014.

Bacterin International Holdings, Inc. to Report Q1, 2015 Results on May 05, 2015

Bacterin International Holdings, Inc. announced that they will report Q1, 2015 results at 5:00 PM, Eastern Standard Time on May 05, 2015

Bacterin International Holdings, Inc., Q1 2015 Earnings Call, May 06, 2015

Bacterin International Holdings, Inc., Q1 2015 Earnings Call, May 06, 2015

Bacterin International Holdings, Inc. Announces Preliminary Unaudited Revenue Results for the First Quarter of 2015

Bacterin International Holdings, Inc. announced preliminary unaudited revenue results for the first quarter of 2015. The company is anticipating total net revenue for the first quarter of 2015 to be in the range of $9.4 million to $9.5 million, representing a year-over-year increase of 5 to 7% when compared to $8.9 million reported for the first quarter of 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BONE:US $3.72 USD +0.05

BONE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biolase Inc $1.64 USD -0.06
Cardica Inc $0.42 USD -0.006
Cogentix Medical Inc $1.65 USD -0.04
Cytori Therapeutics Inc $0.69 USD +0.0211
Stereotaxis Inc $1.77 USD -0.12
View Industry Companies
 

Industry Analysis

BONE

Industry Average

Valuation BONE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BACTERIN INTERNATIONAL HOLDI, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.